{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "9065962", "DateCompleted": {"Year": "1997", "Month": "06", "Day": "12"}, "DateRevised": {"Year": "2004", "Month": "11", "Day": "17"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0176-3679", "JournalIssue": {"Volume": "30", "Issue": "1", "PubDate": {"Year": "1997", "Month": "Jan"}}, "Title": "Pharmacopsychiatry", "ISOAbbreviation": "Pharmacopsychiatry"}, "ArticleTitle": "Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial.", "Pagination": {"StartPage": "1", "EndPage": "5", "MedlinePgn": "1-5"}, "Abstract": {"AbstractText": ["101 outpatients suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment disorder with anxiety) were included in a 25-week multicenter randomized placebo-controlled double-blind trial with WS 1490, a special extract of kava-kava. In the main outcome criterion, the Hamilton Anxiety Scale (HAMA), there was a significant superiority of the test drug starting from week 8 on. WS 1490 was also found to be superior with respect to the secondary outcome variables. HAMA subscores somatic and psychic anxiety, Clinical Global Impression, Self-Report Symptom Inventory-90 Items revised, and Adjective Mood Scale. Adverse events were rare and distributed evenly in both groups. These results support WS 1490 as a treatment alternative to tricyclic antidepressants and benzodiazepines in anxiety disorders, with proven long-term efficacy and none of the tolerance problems associated with tricyclics and benzodiazepines."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Psychiatry, Jena University, Germany."}], "LastName": "Volz", "ForeName": "H P", "Initials": "HP"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Kieser", "ForeName": "M", "Initials": "M"}], "PublicationTypeList": ["Clinical Trial", "Journal Article", "Multicenter Study", "Randomized Controlled Trial"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Pharmacopsychiatry", "NlmUniqueID": "8402938", "ISSNLinking": "0176-3679"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Anxiety Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}], "MeshHeadingList": [{"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Anti-Anxiety Agents"}, {"QualifierName": ["drug therapy", "psychology"], "DescriptorName": "Anxiety Disorders"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Kava"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": [], "DescriptorName": "Outpatients"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Psychiatric Status Rating Scales"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1997", "Month": "1", "Day": "1"}, {"Year": "1997", "Month": "1", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1997", "Month": "1", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["9065962", "10.1055/s-2007-979474"]}}]}